Skip to main content
Erschienen in: Journal of the International AIDS Society 4/2010

Open Access 01.11.2010 | Poster presentation

Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era

verfasst von: AM Cattelan, M Zanchetta, L Sasset, R Petrara, R Freguja, K Gianesin, MG Cecchetto, F Cremona, A De Rossi

Erschienen in: Journal of the International AIDS Society | Sonderheft 4/2010

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Purpose of the study

HAART has greatly modified the course of HIV-1 infection; however, its impact seems to be less favourable on lymphoproliferative disorders associated with Epstein-Barr virus (EBV) than on other AIDS-defining illnesses. The aim of this study was to estimate the relationship between EBV levels and other viro-immunological parameters in HIV-1 infected subjects in the HAART era.

Patients and methods

164 HIV-1 infected patients (pts) who attended the Infectious Diseases Unit of Rovigo Hospital, from July 2007 to December 2009 were included in this study. 28% of patients had HBV and/or HCV coinfections. HIV-1 RNA in plasma was quantified by COBAS Taqman HIV-1 test. HIV-1 DNA and EBV-DNA in peripheral blood mononuclear cells (PBMC) were determined by real-time PCR. Lipopolysaccharide (LPS), a marker of microbial translocation, was determined in plasma samples using a chromogenic assay (Limolus Amebocyte Lysate). B-cell activation was analyzed by flow cytometry using monoclonal antibodies CD19PerCP, CD86APC, and CD69PE.

Results

The median (IQR) EBV-DNA load was 41(1-151) copies/105 PBMC. 48% of pts had CD4 >500 cells/µl and 27% had undetectable HIV viral load. The EBV-DNA level was significantly higher in pts with CD4 below 500 cells/µl than in those with CD4 >500cells/µl [72(14-324) vs 18 (1-80) copies/105; p<0.0001] and in pts with detectable HIV-1 RNA than in those with undetectable viremia [49(7-315) vs 17(1-55) copies/105; p=0.001]. Levels of EBV-DNA were higher in the group of pts with CD4 cell counts >500 cells/µl and high HIV-1 viremia (>1000 copies/ml) than in pts with low viremia, regardless of the immunological status [48(5-153) vs 18(1-60); p=0.015). EBV-DNA was also significantly higher in pts with coinfections than in pts with no coinfections [85(10-527) vs 33(1-114); p= 0.003]. Furthermore, pts with high EBV loads (up to 75th percentile) had higher levels of HIV-1 DNA [40(1-132) vs 10(1-76) HIV-DNA copies/105; p= 0.050) and higher levels of LPS [130(88-244) vs 98(81-134) pg/ml; p=0.024) than pts with low EBV loads. B-cell activation in pts with high EBV loads was confirmed by immunophenotyping; two of these pts developed a B-cell lymphoma.

Conclusions

These findings suggest that HIV-1viremia, other coinfections, and immune activation play an important role in the B-cell stimulation and expansion of EBV-infected cells. Persistent HIV-1 viremia, despite immunereconstitution, may represent a risk factor for the onset of EBV-related cancers.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metadaten
Titel
Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era
verfasst von
AM Cattelan
M Zanchetta
L Sasset
R Petrara
R Freguja
K Gianesin
MG Cecchetto
F Cremona
A De Rossi
Publikationsdatum
01.11.2010
Verlag
BioMed Central
Erschienen in
Journal of the International AIDS Society / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-S4-P213

Weitere Artikel der Sonderheft 4/2010

Journal of the International AIDS Society 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.